SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis

Clinical trial NCT03783416 · RECRUITING

Trial details

NCT number: NCT03783416
Sponsor: Queen Mary University of London
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Relapsing Remitting Multiple Sclerosis Primary Progressive Multiple Sclerosis Secondary Progressive Multiple Sclerosis

Start date: 2020-06-15
Primary completion: 2026-07-31
Enrollment: 72

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.